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Background: CD1d is a widely expressed lipid antigen presenting molecule required for CD1d-restricted invariant
natural killer T (iNKT) cell development. Elevated CD1d expression is detected in CD5+ IL10-producing B cells, called
B10 B cells, and is correlated with poorer prognosis in chronic lymphocytic leukemia (CLL), a CD5+ B cell malignancy
with B10-like functional properties. Whether CD1d expression regulates CD5+ B cell accumulation, IL10 competence,
and antibody production in naïve mice with pathologic CD5+ B cell expansion remains untested.
Results: Using three different transgenic mouse models of benign or leukemic CD5+ B cell expansion, we found that
CD1d was differentially expressed on CD5+ B cells between the three models, but loss of CD1d expression had no
effect on CD5+ B cell abundance or inducible IL10 expression in any of the models. Interestingly, in the CLL-prone
Eμ-TCL1 model, loss of CD1d expression suppressed spontaneous IgG (but not IgM) production, whereas in the
dnRAG1xEμ-TCL1 (DTG) model of accelerated CLL, loss of CD1d expression was associated with elevated numbers of
splenic CD4+ and CD8+ T cells and an inverted CD4+:CD8+ T cell ratio. Unexpectedly, before leukemia onset, all three
transgenic CD1d-deficient mouse strains had fewer splenic transitional B cells than their CD1d-proficient counterparts.
Conclusions: The results show that CD1d expression and iNKT cells are dispensable for the development,
accumulation, or IL10 competence of CD5+ B cells in mice prone to benign or leukemic CLL-like B cell expansion, but
reveal a novel role for iNKT cells in supporting B cell progression through the transitional stage of development in
these animals. These results suggest CD1d-directed therapies to target CLL could be evaded by downregulating CD1d
expression with little effect on continued leukemic CD5+ B cell survival. The data also imply that iNKT cells help restrain
pro-leukemic CD8+ T cell expansion in CLL, potentially explaining a reported correlation in human CLL between
disease progression, the loss of NKT cells, and a paradoxical increase in CD8+ T cells.
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CD1d is a non-polymorphic MHC-like molecule that
functions to present lipid-based antigens to a subset of T
cells expressing natural killer cell lineage markers and a
CD1d-restricted T cell receptor. Most of these CD1d-
restricted T cells express a T cell receptor comprised of a
semi-invariant TCRα chain paired with a member of a
restricted set of TCRβ chains, and are therefore termed
invariant natural killer T (iNKT) cells [1]. In humans,
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ease. Interestingly, a recent report established that murine
and human CLL cells, like B10 cells, are also IL10-
competent [8].
iNKT cells in mice and humans respond to similar an-
tigens in vivo and fulfill similar immunological roles in
both species, although subtle differences in the number,
distribution, and effector function of iNKT cell popula-
tions have been described (for review, see [9]). iNKT
cells play an important role in promoting protective
antibody responses (for review, see [10]). On the other
hand, iNKT cells also function to suppress B cell auto-
reactivity [11, 12]. Paradoxically however, iNKT cells
have been shown to enhance spontaneous autoantibody
secretion by B cells from patients with systemic lupus
erythematosus (SLE) [13], and murine models of this
disease [14]. iNKT cells fail to develop in Cd1d−/− mice
[15], but defects in B cell development have not been re-
ported in these animals.
Previously, we described transgenic mice expressing
catalytically inactive RAG1 (dnRAG1 mice), which de-
velop a benign early-onset CD5+ B cell lymphocytosis with
hypogammaglobulinemia, and exhibit a restricted B cell
receptor repertoire with biased Jκ1 usage consistent with a
defect in B cell receptor editing [16]. The indolent accu-
mulation of CD5+ B cells in dnRAG1 mice is reminiscent
of monoclonal B cell lymphocytosis (MBL), a condition
that generally precedes the onset of CLL [17]. Consistent
with this hypothesis, dnRAG1 transgene expression in the
well-established Eμ-TCL1 model of murine CLL was
found to significantly accelerate disease progression [18].
Given recent evidence that murine and human CLL pos-
sess B10-like phenotypic and functional properties [8], we
hypothesized that CD5+ B cells in dnRAG1 mice and
dnRAG1/Eμ-TCL1 double-transgenic (DTG) mice func-
tionally resemble B10 B cells. We further postulated that
CD1d expression and iNKT cells are required for proper
regulation of CD5+ B cell accumulation, IL10 production,
and spontaneous antibody levels in these animals.
To test these hypotheses, we analyzed CD1d expres-
sion levels in wild-type, dnRAG1, Eμ-TCL1, and DTG
mice, and compared the absolute number of CD5+ B
cells, the frequency of CD5+IL10+ B cells after mitogenic
stimulation in vitro, and the concentration of serum
IgM and IgG in naïve wild-type, dnRAG1, Eμ-TCL1, and
DTG mice on a CD1d-proficient or a CD1d-deficient
strain background. Our findings reveal that CD5+ B cells
in dnRAG1 and DTG mice express higher levels of
CD1d than both CD5+ B cells from Eμ-TCL1 mice and
CD5− B cells from wild-type mice. Nevertheless, CD5+ B
cell accumulation and IL10-competence in dnRAG1, Eμ-
TCL1, and DTG mice were not significantly altered by
loss of CD1d expression and iNKT cells. Interestingly, at
12 weeks of age before leukemia onset in CLL-pronemouse strains, dnRAG1, Eμ-TCL1, and DTG mice all
showed significantly fewer transitional B cells in the
CD1d-deficient strain background compared to their
CD1d-proficient counterparts. In addition, loss of CD1d
expression in Eμ-TCL1 mice led to a significant reduction
in serum IgG. Furthermore, older CD1d-deficient DTG
mice showed significant increases in CD4+ and CD8+ T
cells and an inverted CD4+:CD8+ T cell ratio. Taken to-
gether, these data suggest that CD1d expression and iNKT
cells are dispensable for B10-like CD5+ B cell accumula-
tion and IL10-competence in mice prone to MBL-like and
CLL-like disorders, but iNKT cells play a previously
unrecognized role in regulating B cell progression through
the transitional stages of B cell development. Furthermore,
iNKT cells may promote spontaneous antibody produc-
tion in Eμ-TCL1 mice and regulate T cell expansion in
DTG mice.Methods
Mice
Transgenic dnRAG1, Eμ-TCL1, and DTG (dnRAG1/Eμ-
TCL1 double-transgenic) mice, all on C57Bl/6 back-
grounds, have been described previously [16, 18, 19]. Mice
harboring a conditional (floxed) Cd1d1 allele on a C57Bl/6
background [20] (called Cd1dfl henceforth) were obtained
from the Jackson Laboratory (Cd1d1/Cd1d2tm1.1Aben/J;
note that Cd1d2 is a pseudogene in the C57Bl/6 back-
ground [21]). Our original intent was to use mb1-Cre
transgenic mice [22] to generate conditional Cd1d knock-
out mice in wild-type, dnRAG1, Eμ-TCL1, and DTG strain
backgrounds to evaluate how selective loss of CD1d ex-
pression in B cells affects CD5+ B cell accumulation and
functionality in the different strain backgrounds. However,
due to unexpected Cre-mediated germline deletion of the
Cd1dfl allele, this approach was not feasible. As an alterna-
tive, we bred out the mb1-Cre transgene, and intercrossed
mice harboring the germline-deleted Cd1d allele to gener-
ate Cd1ddel/del mice. The dnRAG1 and Eμ-TCL1 trans-
genes were then bred individually onto the Cd1ddel/del
background, and the two strains were intercrossed to ob-
tain cohorts of Cd1ddel/del wild-type (WT), Cd1ddel/del
dnRAG1, Cd1ddel/del Eμ-TCL1, and Cd1ddel/del DTG mice.
These animals were euthanized at 12 or 36 weeks of age
and analyzed in parallel to age-matched Cd1d+/+ mice
with the same genotype in the experiments described
below. Thus, rather than being a conditional model of
Cd1d gene disruption, Cd1d expression is disrupted in all
cell lineages in Cd1ddel/del mice. All mice were housed in
individually ventilated microisolator cages in an AAALAC
certified animal facility in accordance with university and
federal guidelines, and mouse protocols were approved by
the Creighton University Institutional Animal Care and
Use Committee. See Additional file 1 for further details.
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Single-cell suspensions prepared from spleen and bone
marrow were depleted of red blood cells by hypotonic
lysis, stained with fluorochrome-conjugated antibodies
or CD1d tetramers, and subjected to flow cytometric
analysis as described in Additional file 1.
Analysis of IL10 production
Intracellular IL10 protein induction following in vitro
stimulation with lipopolysaccharide (LPS), phorbol-12-
myristate-13-acetate (PMA), ionomycin, and monensin
(LPS + PIM) was detected by flow cytometry as described
previously [4, 23]. Briefly, 106 splenocytes, depleted of red
blood cells, were incubated in complete medium (RPMI
1640 medium containing 10 % FCS, 200 μg/ml penicillin,
200 U/ml streptomycin, 4 mM L-glutamine, and 50 μM 2-
mercaptoethanol; 100 μL final volume) with LPS (10 μg/
ml, Escherichia coli serotype 0111:B4; Sigma-Aldrich),
PMA (50 ng/ml; Sigma- Aldrich), ionomycin (1 μg/ml;
Sigma-Aldrich), and monensin (2 μM; eBioscience) for
4 h, in 96 well flat-bottom plates. As a control, some sam-
ples were treated with only monensin. For IL-10 detection,
cells were treated with Fc-block reagent (anti-CD16/
CD32, clone 93; eBioscience) before cell surface staining.
Stained cells were fixed and permeabilized using a
Cytofix/Cytoperm kit (BD Pharmingen), according to the
manufacturer’s instructions, and stained with APC-
conjugated mouse anti-IL-10 mAb (JES5-16E3; eBioscience)
or isotype matched control (eB149/10H5; eBioscience).
Immunoglobulin levels
Serum Igs were measured by ELISA with IMMUNO-
TEK mouse IgM and IgG kits (ZeptoMetrix, Buffalo,
NY) according to manufacturer’s instructions. Optical
density was measured with VersaMax microplate reader
(Molecular Devices, Sunnyvale, CA).
Statistics
Collected data were subjected to analysis of variance and
post hoc testing using the PASW Statistics 22.0 software.
A p value < 0.05 was considered significant. Data is pre-
sented as mean ± the standard error of the means.
Results
CD5+ B cells in dnRAG1 and DTG mice express elevated
levels of CD1d
Although the CD5+ B cells accumulating in dnRAG1
mice and DTG mice phenotypically resemble B10 B cells
insofar as CD5 expression is concerned, unlike the B10
B cells described in early studies [4], they do not express
CD21 [18]. We nevertheless considered the possibility
that they functionally resemble B10 B cells for several
reasons. First, previous gene expression profiling analysis
of CD5+ B cells from dnRAG1, Eμ-TCL1, and DTG miceshowed that these cells all express IL10 at higher levels
than CD5− B cells from WT mice [18]. Second, a recent
study by DiLillo et al. showed that human CLL cells and
CLL-like CD5+ B cells from Eμ-TCL1 mice, which we
have shown to be CD21− [18], can be stimulated to ex-
press IL10 by LPS + PIM treatment in vitro [8]. Third,
analysis of the gene expression data from our previous
study [18] provided evidence that Cd1d expression is
higher in CD5+ B cells from dnRAG1 mice and DTG
mice than either CD5− B cells from WT mice or CD5+ B
cells from Eμ-TCL1 mice at 12 and 36 weeks of age.
These time points were chosen for the following reasons:
(a) at 12 weeks of age, CD5+ B cells represent a large
fraction of splenic B cells in dnRAG1 and DTG mice,
but only a small fraction of splenic B cells in WT and
Eμ-TCL1 mice; and (b) the 36 week time point repre-
sents the approximate median life span of DTG mice
where CLL onset is evident [18]. Flow cytometric analysis
confirmed that at both time points, surface CD1d protein
levels on CD5+ B cells from dnRAG1 mice and DTG mice
were elevated compared to CD5− and CD5+ B cells from
WT mice or CD5+ B cells from Eμ-TCL1 mice (Fig. 1).
CD5+ B cells from wild-type and transgenic mice are IL10
competent
B10 B cells were initially characterized as a splenic
CD1dhiCD5+CD19hi population that expresses IL10 after
in vitro stimulation with LPS + PIM. Monensin inhibits se-
cretion, allowing cytoplasmic IL10 protein to accumulate
to levels detectable by flow cytometry after intracellular
staining with an IL10-specific monoclonal antibody [4].
LPS enhances, but is not required for, IL10 production
under these conditions [24]. Because the CD5+ B cells ac-
cumulating in dnRAG1 and DTG mice share the CD1dhi
phenotype of B10 B cells, we investigated whether these
cells support activation-induced IL10 expression like B10
cells. To test this possibility, splenocytes from 12 or
36 week-old WT, dnRAG1, Eμ-TCL1, and DTG mice were
stimulated with LPS + PIM for 4 h in vitro and analyzed
for intracellular IL10 protein by flow cytometry as de-
scribed [4, 23]. We find that among gated CD19+ B cells
at 12 weeks of age, ~23 % of CD5+ B cells from WT mice
stained IL10+ after LPS + PIM treatment. Interestingly,
this value was slightly higher in Eμ-TCL1 mice (~38 %),
and even more elevated in dnRAG1 and DTG mice
(~62 % and 51 %, respectively) (Fig. 2a and c). CD5− B
cells from the same animals showed little if any inducible
IL10 expression (Fig. 2a). No staining was detected using
an isotype control antibody, or after monensin treatment
alone. The latter result shows that, despite being upregu-
lated at the transcript level in transgenic CD5+ B cells
[18], IL10 protein is not expressed at sufficient levels to be
detectable by flow cytometry under these conditions.
Similar results were obtained at 36 weeks, although the
Fig. 1 CD5+ B cells in dnRAG1 and DTG mice express high levels of CD1d. a-b Cohorts of 12 week-old (a) and 36 week-old (b) mice were analyzed
for CD1d expression on CD19+ and CD5− or CD5+ B cells from WT, dnRAG1, Eμ-TCL1 and DTG mice. (Left Panel) Overlay of CD1d expression on CD19
+CD5− (WT) or CD19+CD5+ (WT, dnRAG1, Eμ-TCL1 and DTG) B cells from representative animals. (Right panel) Mean fluorescence intensity of CD1d
staining in the gated populations in the left panel (n = 4–6 animals/genotype). Statistically significant differences (p < 0.05) were only detected in
comparisons between dnRAG1 mice and the other mouse genotypes (a, vs WT mice; b, vs Eμ-TCL1 mice; c, vs DTG mice)
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stained IL10+ more closely resembled dnRAG1 mice at
this time point than at 12 weeks of age (Fig. 3a and c).
Taken together, these results establish that CD5+ B cells in
dnRAG1 and DTG mice share the feature of IL10 compe-
tence that B10 B cells and CD5+ B cells in older Eμ-TCL1
mice possess.
CD1d expression and iNKT cells are dispensable for CD5+
B cell accumulation and IL10 competence in dnRAG1,
Eμ-TCL1, and DTG mice
The observation that CD5+ B cells in dnRAG1 and
DTG mice accumulate more rapidly and express
higher levels of CD1d than CD5+ B cells from Eμ-
TCL1 mice caused us to question the requirement for
CD1d expression and the presence of iNKT cells inthe expansion and function of these cells, particularly
in light of evidence suggesting a positive correlation
between elevated CD1d expression levels and poor
prognosis in CLL [7], and reports suggesting that
NKT-like cells are reduced in progressive CLL [25, 26]
(although another study found normal numbers of
iNKT cells in a cohort of untreated CLL patients [27]).
To directly test this possibility, we acquired mice har-
boring a conditional Cd1d1 allele [20], from which a
germline-deleted Cd1d allele was obtained to generate
Cd1ddel/del mice (see Material and Methods). The
dnRAG1 and Eμ-TCL1 transgenes were crossed onto
the Cd1ddel/del background, and then intercrossed to
obtain cohorts of Cd1ddel/del WT, dnRAG1, Eμ-TCL1,
and DTG mice that were analyzed in parallel to their
Cd1d+/+ counterparts.
Fig. 2 CD5+ B cells in 12 week-old dnRAG1 and DTG mice support inducible IL10 expression in vitro, but IL10 competence is CD1d-independent.
a-b Splenocytes from 12 week-old wild-type, dnRAG1, Eμ-TCL1, and DTG mice on a Cd1d+/+ (a) or Cd1ddel/del (b) background were incubated with
monensin alone or LPS + PIM for 4 h. After permeabilization, the cells were stained with IL-10-specific or isotype-control monoclonal antibody (Ab) as
indicated. Gated CD19+ B cells were analyzed for CD5 and IL10 expression. The percentage of cells in each quadrant is shown for representative
animals. c The mean percentage of total CD5+ B cells staining positive for IL10 for n = 4 mice/genotype is plotted in bar graph format.
Error bars represent the SEM. Statistically significant (p < 0.05) differences between groups of WT and transgenic animals with the same
Cd1d genotype are indicated (a, vs dnRAG1; b, vs Eμ-TCL1; c, vs DTG). No significant differences between Cd1d+/+ and Cd1ddel/del animals
with the same transgenes were detected
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number of splenic CD19+CD5+ B cells in Cd1ddel/del
WT, dnRAG1, Eμ-TCL1, and DTG mice was not sig-
nificantly different than in their Cd1d+/+ counterparts
(Additional file 2: Table S1), and these cells weresimilarly competent to express IL10 after LPS + PIM
treatment (compare Fig. 2a to b; see Fig. 2c), despite
the loss of surface CD1d on B cells and the expected
absence of iNKT cells (Additional file 3: Figure S1A).
Similar results were obtained for 36 week-old animals;
Fig. 3 Eμ-TCL1 mice at 36 weeks of age show increased inducible IL10 expression in vitro compared to 12 weeks, but IL10 competence remains
CD1d-independent. (a-c) Splenocytes from 36 week-old wild-type, dnRAG1, Eμ-TCL1, and DTG mice on a Cd1d+/+ or Cd1ddel/del background were
analyzed as Fig. 2. No significant differences between Cd1d+/+ and Cd1ddel/del animals with the same transgenes were detected
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cells and lower IL10-competence was noted in Cd1ddel/del
Eμ-TCL1 mice compared to their Cd1d+/+ counterparts
(see Additional file 4: Table S2; compare Fig. 3a to b; see
Fig. 3c), the differences were not statistically significant
due to greater variability in the absolute numbers of CD5+
B cells found in Cd1ddel/del Eμ-TCL1 mice at this age.
Thus, we conclude from these data that CD1d and iNKT
cells are dispensable for the accumulation and IL10competence of CD5+ B cells in WT, dnRAG1, Eμ-TCL1,
and DTG mice.
CD1d expression and iNKT cells are required for normal
progression through the transitional stage of B cell
development and for regulating T cell expansion in DTG mice
Besides the loss of iNKT cells, there were two other cell
populations that were significantly affected by loss of
CD1d expression in these studies. The first was the
Fig. 4 (See legend on next page.)
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Fig. 4 Progression through the transitional stages of B cell development is impaired in Cd1ddel/del mice. a Gated splenic CD19+CD5− B cells from
12 week-old or 36 week-old WT, dnRAG1, Eμ-TCL1 and DTG mice on a Cd1d+/+ (+/+) or Cd1ddel/del (del/del) background were initially segregated into
transitional (trans.) and mature B cell subsets based on differential expression of AA4.1 and B220. Transitional (AA4.1+B220hi) and mature (AA4.1−B220hi)
B cell subsets were further separated into T1-T3, marginal zone (MZ) and follicular mature (FM) populations based on differential expression of IgM,
CD21, and CD23 using the gating strategy found at the bottom of the figure. The percentage of cells within the identified gates is
shown for representative animals. Data collected from n = 4–6 animals/genotype were used to calculate the absolute number of cells in
each population, and are summarized in Additional file 2: Table S1 and Additional file 4: Table S2. b Values for the mean absolute number of total
transitional B cells (B220hiAA4.1+CD5−) and for each transitional B cell subset (T1-T3) are plotted in bar graph format for the 12 week time point in
(a). Error bars represent the standard error of the mean. Statistically significant differences (p < 0.05) between groups of Cd1d+/+ or Cd1ddel/del mice with
the same transgenic background are identified by an asterisk
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nificantly reduced (40–50 %) in 12 week-old Cd1ddel/del
dnRAG1, Eμ-TCL1, and DTG mice compared to their
Cd1d+/+ counterparts, due mostly to loss of transitional
T1 B cells, (Fig. 4a-b; Additional file 2: Table S1). While
the total number of transitional B cells was also slightly
reduced in WT mice, the difference was not statistically
significant at this time point. Similar trends were also
noted at 36 weeks, but the differences were not statisti-
cally significant (Fig. 4a; Additional file 4: Table S2). The
second was the striking increase in the abundance of CD8
+ T cells, and to a lesser extent CD4+ T cells, in 36 week-
old Cd1ddel/del DTG mice compared to their Cd1d+/+
counterparts that resulted in an inverted CD4:CD8 T cell
ratio in Cd1ddel/del DTG mice (Fig. 5; Additional file 4:
Table S2). These increases were not evident in 12 week-
old DTG mice despite the abundance of CD5+ B cells in
these animals at this time point (Additional file 2: Table
S1), suggesting this outcome is correlated with disease
progression in DTG mice. Thus, we conclude from these
data that CD1d expression and iNKT cells are required for
efficient progression through the transitional stage of B
cell development, and for regulating T cell expansion in
DTG mice.
Cd1d regulates spontaneous antibody production in
Eμ-TCL1 mice, but not WT, dnRAG1, or DTG mice
In previous studies, we demonstrated that naïve dnRAG1
and DTG mice exhibit hypogammaglobulinemia, which
may reflect a mechanism to restrain antibody production
by B cells in which autoreactivity is enforced by a defect in
receptor editing due to dnRAG1 transgene expression
[18]. Given the CD1dhi phenotype of the CD5+ B cells
accumulating in these animals, and previous reports that
iNKT cells play a role in suppressing B cell autoreactivity
[11, 12], we hypothesized that dnRAG1 and DTG mice
lacking iNKT cells would show increased spontaneous
antibody production than their CD1d-proficient counter-
parts. However, we found that serum IgM and IgG levels
between naïve Cd1ddel/del dnRAG1 and DTG mice and
their Cd1d+/+ counterparts were not significantly different
at either 12 or 36 weeks of age (Fig.6a-b). Notably, IgMand IgG levels in both of these backgrounds remained
below those found in comparable WT mice at both time
points. Therefore, we conclude that iNKT cells are not
responsible for sustaining hypogammaglobulinemia ob-
served in dnRAG1 and DTG mice. Interestingly, we note
that Cd1ddel/del Eμ-TCL1 mice showed significantly re-
duced IgG levels compared to their Cd1d+/+ counterparts
at 12 weeks of age (Fig.6a). This trend was also detected at
the 36 week time point, but the difference was not statisti-
cally significant (Fig. 6b). Taken together, these data sug-
gest a role for iNKT cells in promoting IgG production in
Eμ-TCL1 mice.
Discussion
CD1d is a widely expressed, non-polymorphic, MHC
Class I-like lipid antigen-presenting molecule. CD1d ex-
pression is elevated on a normal subset of immunoregu-
latory CD5+ B cells, called B10 B cells, which have a
defining feature of producing IL10 in response to stimu-
lation by LPS + PIM in vitro. In pathological CD5+ B cell
conditions, elevated CD1d expression has been corre-
lated with unmutated Ig gene usage and poor prognosis
in human CLL [6, 7]. Like B10 B cells, CD5+ cells in
human CLL and the murine Eμ-TCL1 model of this dis-
ease also support inducible IL10 expression [8]. Whether
CD1d expression is required to support the development
and accumulation of IL10-competent, CD5+ B cells in a
pathological context has not been formally investigated.
Likewise, whether iNKT cells play a role in regulating B
cell accumulation and/or spontaneous production of im-
munoglobulins under conditions of pathological CD5+ B
cell expansion remain unclear.
Using three different transgenic strains of mice repre-
senting an early-onset benign CD5+ B cell lymphocytosis
(dnRAG1 mice), an established murine model of CLL
(Eμ-TCL1 mice), and a model of accelerated murine
CLL progression (DTG mice), we have confirmed the
earlier observation that a subset of CD5+ B cells in Eμ-
TCL1 mice (and WT mice) support inducible IL10 pro-
duction after LPS + PIM treatment in vitro [8], and
established here that splenic CD5+ B cells accumulating
in dnRAG1 and DTG mice are also IL10 competent.
Fig. 5 Loss of CD1d expression in 36 week-old DTG mice is associated with expansion of splenic T cells, particularly CD8+ T cells. a Gated splenic
CD3+B220− lymphocytes were analyzed for CD4 and CD8 expression. The percentage of cells within the identified gates or quadrants is shown
for representative animals. Note that in DTG mice, the B220− gate does not exclude all CD5+ B cells, which are highly abundant and express
variably low levels of B220 in these animals. Data collected from n = 4–6 animals/genotype were used to calculate the absolute number of cells
in each population, and are summarized in Additional file 4: Table S2. b Values for the mean absolute number of CD4+ and CD8+ T cells determined
from (a) are plotted in bar graph format. Error bars represent the standard error of the mean. Statistically significant differences (p < 0.05) between
groups of Cd1d+/+ or Cd1ddel/del mice with the same transgenic background are identified by an asterisk
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cell compartment in these experiments is significantly
higher for dnRAG1 and DTG mice compared to both
WT and Eμ-TCL1 mice at 12 weeks of age, but at
36 weeks, the frequency of CD5+IL10+ B cells in Eμ-
TCL1 mice rises so that these differences are no longer
significant. Although the mechanistic basis for increasing
IL10 competence among CD5+ B cells in Eμ-TCL1 miceremains unclear, we speculate that this observation re-
flects the gradual replacement of natural B10 B cells by
leukemic B10-like B cells as the animal ages. Neverthe-
less, the data presented here clearly demonstrate that
CD1d expression and the presence of iNKT cells are
both dispensable for the development, accumulation,
and IL10-competence of CD5+ B cells in all three strains
of transgenic mice. Since CD1d is expressed in both mice
Fig. 6 Loss of CD1d expression does not significantly affect spontaneous antibody production in dnRAG1 and DTG mice. Serum IgM and IgG was
measured from 12 (a) and 36 (b) week-old WT, dnRAG1, Eμ-TCL1, and DTG mice on a Cd1d+/+ or Cd1ddel/del background (closed circles or open
triangles, respectively). Individual values and means (identified by horizontal bar) are shown for each group; statistically significant differences
between groups are indicated
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in B cells in both species in vivo [1, 10], this finding may
have important implications for the potential success of
therapeutic strategies targeting CD1d in CLL, because
downregulation of CD1d as an evasion mechanism would
be expected to have little or no effect on the continued
survival and proliferation of the leukemic cells.
iNKT cells have been implicated in both promoting
humoral immune responses to exogenous antigen and
in suppressing B cell autoimmunity [10–12]. Because
dnRAG1 and DTG mice show pronounced hypogamma-
globulinemia associated with a defect in receptor editing,
and because CD5+ B cells accumulating in these animals
have a CD1dhi immunophenotype, we reasoned that iNKT
cells may be responsible for suppressing antibody produc-
tion by B cells developing in these mouse strains. How-
ever, loss of iNKT cells did not significantly alter IgM or
IgG levels in naïve dnRAG1 and DTG mice, suggesting
that the suppression of antibody production in these ani-
mals is enforced by other mechanisms. Interestingly, how-
ever, serum IgG (but not IgM) levels were significantlyreduced in naïve Eμ-TCL1 mice on a Cd1ddel/del back-
ground compared to those on a Cd1d+/+ background at
12 weeks of age, and this trend was also evident at the
36 week time point. Thus, in Eμ-TCL1 mice, iNKT cells
appear to promote IgG production in the absence of
exogenous antigenic stimulation, reminiscent to what has
been reported in vitro in SLE patients and murine models
of this disease [13, 14]. The observation that an iNKT
cell-dependent reduction in IgG levels was not ob-
served in naïve wild-type mice argues that different
mechanisms regulate IgG production in naïve wild-
type and Eμ-TCL1 mice.
To our knowledge, there are no previous reports
describing B cell developmental defects in Cd1d−/− mice.
Consistent with this observation, no significant differences
in the absolute numbers of cells in various developmental
and mature B cell subsets were identified between WT
Cd1d+/+ and WT Cd1ddel/del mice at 12 weeks of age. Inter-
estingly, however, we noted a significant decrease in the ab-
solute number of splenic transitional (B220+AA4.1+) B cells
in all three transgenic strains of mice on a Cd1ddel/del
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background, particularly manifested at the transitional T1
stage. This trend was also noted in 36 week-old animals,
but the differences were not statistically significant, possibly
due to confounding disease progression in Eμ-TCL1 and
DTG mice. Because dnRAG1, Eμ-TCL1, and DTG mice
are all predisposed to accumulating CD5+ B cells over time
[16, 18, 19], and CD5+ B cells in general have a predilection
toward auto- and poly-reactivity [28], particularly against
membrane-associated antigens which includes lipid-based
molecules that can be presented on CD1d [28], these data
raise the possibility that iNKT cells play a previously
unrecognized role in mediating tolerance induction in de-
veloping B cells reactive toward membrane-associated lipid
antigens. The reduced numbers of splenic transitional B
cells in transgenic mice bred onto a Cd1ddel/del background
suggests the normal role for the iNKT cells in this context
is to provide pro-survival signals to transitional B cells
reactive toward membrane-associated antigens, perhaps to
facilitate receptor editing at the immature B cell stage of
development to rescue B cell autoreactivity.
The increase in splenic T cell numbers, particularly
CD8+ T cells, in 36 week-old Cd1ddel/del DTG mice com-
pared to Cd1d+/+ DTG mice was unexpected, and raises
the possibility that CD1d expression and/or iNKT cells
regulate splenic T cell expansion in DTG mice during
disease progression. There is some precedence for the
role of iNKT cells in this process. Goubier et al. reported
that iNKT cell deficiency enhanced skin inflammation in
a model of contact hypersensitivity associated with in-
creased recruitment of effector CD8+ T cells into
antigen-exposed skin [29]. In addition, Ho et al. showed
that activation of iNKT cells could suppress the prolifer-
ation of antigen-specific CD8+ T cells in vitro [30]. Fi-
nally, in a model of Listeria monocytogenes infection,
Han et al. provided evidence that a hepatic population of
NKT cells can suppress CD4+ and CD8+ T cell prolifera-
tion without interfering with their function in vitro and
in vivo [31]. Taken together, these data suggest a model in
which iNKT cells help restrain T cell proliferation in DTG
mice as leukemia progresses. The observation that
36 week-old Cd1ddel/del and Cd1d+/+ DTG mice have
similar absolute numbers of CD5+ B cells tends to
reinforce this model by arguing against the possibility that
the expanded populations of T cells in Cd1ddel/del DTG
mice are contributing to greater clearance of leukemic
CD5+ B cells in these animals. Interestingly, reminiscent
of Cd1ddel/del DTG mice, human CLL patients often show
a paradoxical elevation in the absolute number of T cells,
due mainly to an increase of CD8+ T cells [32]. This obser-
vation has led to the suggestion that these T cells foster an
environment to promote leukemic cell growth or survival.
The data presented here raise the possibility that in
human CLL, iNKT cells are responsible for restraining Tcell proliferation to control CLL progression, which would
be consistent with reports correlating loss of NKT-like
cells with disease progression in human CLL [25, 26].
Conclusions
Here we show that, similar to CLL-like B cells in Eμ-TCL1
mice, CD1dhiCD5+ B cells accumulating in dnRAG1 and
DTG mice are IL10-competent. However, in all three
murine models, loss of CD1d expression and iNKT cells
had no effect on CD5+ B cell development, accumulation,
or IL10 competence. These results imply that strategies to
therapeutically target CD1d in CLL could be evaded by
downregulating CD1d expression with little effect on con-
tinued leukemic cell survival. On the other hand, our find-
ings associating the loss of CD1d expression and iNKT
cells with a reduction in transitional B cell numbers in all
three strains of transgenic mice, the suppression of spon-
taneous IgG production in Eμ-TCL1 mice, and the eleva-
tion of T cell numbers and an inversion of the CD4:CD8
T cell ratio in older DTG mice reveal new roles for iNKT
cells in promoting progression of potentially polyreactive
B cells through the transitional stage of B cell develop-
ment, stimulating IgG production in Eμ-TCL1 mice, and
restraining CD8+ T cell expansion in DTG mice. The lat-
ter observation may help explain reported associations in
CLL between disease progression, loss of NKT-like cells,
and a paradoxical increase in CD8+ T cells.
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